

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

46342/56000

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

09/869098

INTERNATIONAL APPLICATION NO.

PCT/JP/07198

INTERNATIONAL FILING DATE

22 December 1999

PRIORITY DATE CLAIMED

24 December 1998

TITLE OF INVENTION

UCP-2 Promoter DNA

APPLICANT(S) FOR DO/EO/US

Yukio TOYODA, Makoto KOBAYASHI, Shigeru IGAKI

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4. ☐ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☒ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☒ A copy of the International Search Report (PCT/ISA/210).

Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22. ☒ Certificate of Mailing by Express Mail
23. ☒ Other items or information:

Sequence Listing on Computer disk and hardcopy (2) pages;

PCT/IB/332

PCT/IPEA/408

Information Disclosure Statement (5) pages;

PCT/IB/332

Form/IB/304 Form PCT/RO/101

PCT/RO/105

Form/IB/301 Form/PCT/IPEA/416

09/869098

PCT/JP/07198

46342/56000

24. The following fees are submitted:

CALCULATIONS PTO USE ONLY

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

- ☐ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO **\$1000.00**
- ☒ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO **\$860.00**
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO **\$710.00**
- ☐ International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) **\$690.00**
- ☐ International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) **\$100.00**

ENTER APPROPRIATE BASIC FEE AMOUNT =**\$860.00**Surcharge of **\$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).**\$0.00**

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	21 - 20 =	1	x \$18.00
Independent claims	6 - 3 =	3	x \$80.00

\$18.00**\$240.00**Multiple Dependent Claims (check if applicable). ☐**\$0.00****TOTAL OF ABOVE CALCULATIONS =****\$1,118.00**☐ Applicant claims small entity status. (See 37 CFR 1.27). The fees indicated above are reduced by 1/2.**\$0.00****SUBTOTAL =****\$1,118.00**Processing fee of **\$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).**\$0.00****TOTAL NATIONAL FEE =****\$1,118.00**Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). ☐**\$0.00****TOTAL FEES ENCLOSED =****\$1,118.00**

Amount to be:	\$
refunded	
charged	\$

- a. ☒ A check in the amount of **\$1,118.00** to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **04-1105** A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

David G. Conlin, Esq. (Reg. No. 27,026)
 Kathryn A. Piffat, Ph.D., Esq. (Reg. No. 34,901)
 Dike, Bronstein, Roberts & Cushman
 Intellectual Property Practice Group
 EDWARDS & ANGELL, LLP
 P.O. Box 9169
 Boston, MA 02209
 Telephone: 617/439-4444

Kathryn A. Piffat, Ph.D.
 SIGNATURE

Kathryn A. Piffat, Ph.D.

NAME

34,901

REGISTRATION NUMBER

June 21, 2001

DATE

Docket No. 46342/56000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Y. TOYODA et al.
SERIAL NO.: 09/869,098
FILED: June 21, 2001
FOR: UCP-2 Promoter DNA

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

PRELIMINARY AMENDMENT

Please amend the above-identified application as follows:

In the Specification:

Marked copies of the specification revisions have been provided in the attached Appendix 1.

Please replace the paragraph at page 7, lines 1-3, with the following paragraph:

-- Figure 2 shows the base sequence of cDNA containing the human UCP - 2 promoter region cloned in Example 1 (continued from Figure 1 to Figure 3). --

Please replace the paragraph at page 23, line 29, to page 24, line 4, with the following paragraph:

-- EcoRI fragment (3.5 kbp) was isolated from the genomic human UCP-2 DNA and blunted using Blunting High Kit (TOYOBO Co.), and then ligated to SmaI-digested pGL3 - Basic plasmid DNA. Following the above procedure, human UCP - 2 promoter/luciferase vector (pGL3-UCP2) was constructed in which the base number 1 - 3505 shown in Figures 1 to 6 was inserted into pGL3 - Basic vector. The constructed human UCP-2 promoter/luciferase vector was transiently transfected in

09869098-092001